• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

    3/17/25 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email

    Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic.

    Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets.

    Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing.

    Investigational new drug (IND) application cleared by U.S. Food and Drug Administration (FDA) for ST-503 for treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Expect to commence patient enrollment and dosing in mid-2025.

    Demonstrated nonclinical proof of concept in prion disease. A single intravenous infusion of Sangamo's zinc finger repressor (ZFR) significantly reduced expression of prion mRNA and protein in the mouse brain and extended mouse survival.

    Aligned with FDA on clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec in Fabry disease, using expected data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

    Announced updated Phase 1/2 STAAR study data that showed sustained benefit, improvements in kidney function and favorable safety profile.

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results.

    "I am pleased with Sangamo's pipeline progress since the start of 2024. We advanced our two prioritized neurology therapies towards the clinic, securing our first ever neurology IND; we showed we are a collaborator of choice for neurotropic capsids, with the announcement of two blue-chip pharma agreements for our STAC-BBB capsid, with negotiations advancing for a third potential agreement; and we have a clear regulatory pathway to Accelerated Approval in Fabry disease, which could reduce the time to potential approval by approximately three years," said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. "We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future. This will be an important year for the Company as we plan to begin patient enrollment and dosing in mid-2025 for our clinical study in iSFN, which we believe has the potential to transform the chronic neuropathic pain landscape, and as we prepare for an anticipated BLA submission in Fabry disease in the second half of the year."

    Recent Business Highlights

    Corporate Updates

    • Announced in December a capsid license agreement with Astellas Gene Therapies, Inc. (Astellas) to deliver genomic medicines for neurological diseases. Agreement grants Astellas a worldwide exclusive license to STAC-BBB for up to five potential neurological disease targets. Received a $20 million upfront license fee from Astellas and eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential neurology disease targets, as well as tiered royalties on potential net sales.
    • Announced in December that Sangamo is scheduled to regain full rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A that it has co-developed with, and licensed to, Pfizer, Inc. (Pfizer), following a decision by Pfizer to terminate the global collaboration and license agreement between the parties. Sangamo continues to explore how to maximize the value of the SB-525 program, including a search for a potential new collaboration partner.

    Core Neurology Pipeline

    Chronic Neuropathic Pain – ST-503

    • IND application cleared by the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain.
    • Preparing for a Phase 1/2 study of ST-503 to assess the safety, tolerability and preliminary efficacy of a one-time dose administered intrathecally to patients with intractable pain due to iSFN.
    • Expect to commence patient enrollment and dosing in mid-2025, with preliminary proof of efficacy data anticipated in Q4 2026.

    Prion Disease

    • Clinical Trial Authorisation (CTA) enabling activities continue to advance for Sangamo's product candidate to treat prion disease, leveraging STAC-BBB.
    • Published a manuscript in bioRxiv titled, "Zinc Finger Repressors mediate widespread prion depletion from the nonhuman primate brain and profoundly extend survival in prion disease mice" demonstrating nonclinical proof of concept for this approach. A single intravenous infusion of Sangamo's ZFR significantly reduced expression of prion mRNA and protein in the mouse brain, extended mouse survival and improved an array of molecular, histological, biomarker and behavior readouts – even when administered post-symptomatically to mice with prion disease. In addition, a single intravenous administration of the prion ZFR, delivered via STAC-BBB to nonhuman primates, resulted in potent and widespread reduction of prion expression in transduced neurons throughout the brain.
    • A CTA submission is expected in Q1 2026, with preliminary clinical data anticipated in Q4 2026.

    Novel Adeno-Associated Virus (AAV) Capsid Delivery Technology

    • Actively engaged in advanced contract negotiations with a potential collaborator for a third STAC-BBB license agreement for use in delivering intravenously administered genomic medicines for certain specified neurological diseases.

    Clinical – Fabry Disease

    • Presented updated Phase 1/2 STAAR study data at the 21st Annual WORLDSymposium in San Diego, CA in February 2025 showing sustained benefit, improvements in kidney function and a favorable safety profile, following a single administration of isaralgagene civaparvovec in 33 adults with Fabry disease.
    • Elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the September 12, 2024 data cutoff date.
    • Positive mean estimated glomerular filtration rate (eGFR) slope of 3.061 mL/min/1.73m2/year (95% confidence interval: 0.863, 5.258) was observed in the 23 patients who had reached at least one-year follow-up, indicating notable improvements in renal function.
    • All 18 patients who began the study on enzyme replacement therapy (ERT) have been withdrawn from, and remain off, ERT as of March 17, 2025.
    • Significant improvements continued to be observed in the short form-36 (SF-36) quality of life (QoL) scores reported, with a mean change in General Health score of 10.6. Significant improvements in physical component, bodily pain, physical, vitality, social function, and emotional SF-36 scores were also observed.
    • Enrollment and dosing are complete in the Phase 1/2 STAAR study.
    • The FDA has provided a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec, agreeing that data from the ongoing Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at 52 weeks across all patients as an intermediate clinical endpoint.
    • The 52-week eGFR slope data from all enrolled patients in the Phase 1/2 STAAR study will be available in the first half of 2025. A potential Biologics License Application (BLA) submission is anticipated in the second half of 2025.
    • Sangamo is advancing BLA preparation activities for isaralgagene civaparvovec, while continuing to engage in business development negotiations for a potential Fabry commercialization agreement.

    Fourth Quarter and Full Year 2024 Financial Results

    Consolidated net loss for the fourth quarter ended December 31, 2024 was $23.4 million, or $0.11 per share, compared to consolidated net loss of $60.3 million, or $0.34 per share, for the same period in 2023. For the year ended December 31, 2024, consolidated net loss was $97.9 million, or $0.49 per share, compared to consolidated net loss of $257.8 million, or $1.48 per share, for the year ended December 31, 2023.

    Revenues

    Revenues for the fourth quarter ended December 31, 2024 were $7.6 million, compared to $2.0 million for the same period in 2023.

    The increase of $5.5 million in revenues was primarily attributed to $6.5 million and $0.8 million in revenues relating to our license agreements with Astellas Gene Therapies, Inc., or Astellas, and Genentech, Inc., respectively, partially offset by revenue decreases in other collaborations.

    Revenues were $57.8 million in 2024, compared to $176.2 million in 2023.

    The decrease of $118.4 million in revenues in 2024 compared to 2023 was primarily attributed to decreases of $134.8 million and $12.2 million in revenues relating to our collaboration agreements with Biogen and Novartis, respectively, due to the termination of these collaboration agreements in June 2023, a decrease of $20.5 million in revenue relating to our collaboration agreement with Kite, which expired pursuant to its terms in April 2024, a decrease of $4.7 million in revenue relating to our license agreements with Sigma and Ligand, and a decrease of $2.7 million in revenue relating to our other license agreements. These decreases were partially offset by $50.0 million in revenue relating to our license agreement with Genentech and $6.5 million in revenue relating to our license agreement with Astellas.

    GAAP and Non-GAAP Operating Expenses

    Three Months Ended Year Ended
    December 31, December 31,
    (In millions)

     

    2024

     

     

    2023

     

     

    2024

     

     

    2023

     

     
    Research and development

    $

    23.6

     

    $

    50.7

     

    $

    111.5

     

    $

    234.0

     

    General and administrative

     

    9.9

     

     

    13.1

     

     

    44.8

     

     

    61.2

     

    Impairment of long-lived assets

     

    -

     

     

    0.3

     

     

    5.5

     

     

    65.5

     

    Impairment of goodwill and indefinite-lived intangible assets

     

    -

     

     

    -

     

     

    -

     

     

    89.5

     

    Total operating expenses

     

    33.5

     

     

    64.1

     

     

    161.8

     

     

    450.2

     

    Impairment of long-lived assets

     

    -

     

     

    (0.3

    )

     

    (5.5

    )

     

    (65.5

    )

    Impairment of goodwill and indefinite-lived intangible assets

     

    -

     

     

    -

     

     

    -

     

     

    (89.5

    )

    Depreciation and amortization

     

    (1.2

    )

     

    (1.8

    )

     

    (5.1

    )

     

    (15.1

    )

    Stock-based compensation expense

     

    (3.3

    )

     

    (6.1

    )

     

    (12.4

    )

     

    (27.4

    )

    Non-GAAP operating expenses

    $

    29.0

     

    $

    55.9

     

    $

    138.8

     

    $

    252.7

     

    Total operating expenses on a GAAP basis for the fourth quarter ended December 31, 2024 were $33.5 million compared to $64.1 million for the same period in 2023. Non-GAAP operating expenses, which exclude impairment charges, depreciation and amortization and stock-based compensation expense as shown in the reconciliation table above, for the fourth quarter ended December 31, 2024 were $29.0 million, compared to $55.9 million for the same period in 2023.

    Total operating expenses on a GAAP basis in 2024 were $161.8 million compared to $450.2 million in 2023. Non-GAAP operating expenses, which exclude impairment charges, depreciation and amortization and stock-based compensation expense as shown in the reconciliation table above, were $138.8 million in 2024 compared to $252.7 million in 2023.

    The decrease in total operating expenses on a GAAP basis was primarily driven by cost reductions resulting from the strategic realignment of the business, which included a lower headcount due to the restructuring of operations and corresponding reductions in workforce announced during 2023. Additionally, the decrease reflects intentional reprioritization of research and development investments, with a focused shift toward advancing the neurology pipeline. Other contributing factors included lower impairment charges recorded in the current year, lower preclinical and clinical expenses due to program deferrals, a decrease in restructuring charges related to the 2023 restructuring of operations, a decrease in depreciation due to reduced carrying values as a result of impairment charges recorded in 2023, and a decrease in external professional services, facilities, and infrastructure-related costs.

    Cash and Cash Equivalents

    Cash and cash equivalents as of December 31, 2024 were $41.9 million, compared to cash, cash equivalents and marketable securities of $81.0 million as of December 31, 2023. Based on our current operating plan, we believe that our cash and cash equivalents as of December 31, 2024, together with $10.1 million generated to date through our at-the-market offering program in 2025 and the $5.0 million payment expected from Pfizer by the end of March, will be sufficient to fund our planned operations into the middle of the second quarter of 2025.

    Financial Guidance for 2025

    • 2025 operating expenses on a non-GAAP basis are expected to be roughly in line with 2024, reflecting our intention to operate a lean neurology-focused business and to continue advancing isaralgagene civaparvovec towards a potential BLA submission, while engaging in business development negotiations for a potential Fabry commercialization agreement.
    • On a GAAP basis, we expect total operating expenses in the range of approximately $135 million to $155 million in 2025, which includes estimated non-cash stock-based compensation expense, and depreciation and amortization.
    • We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $7 million, and estimated depreciation and amortization of approximately $3 million, in the range of approximately $125 million to $145 million in 2025, consistent with the prior year.

    Upcoming Events

    Sangamo plans to participate in the following events:

    • Jefferies Global Healthcare Conference, June 3-5, 2025
    • Wells Fargo Healthcare Conference, September 3-5, 2025

    Access links for available webcasts for investor conferences will be available on the Sangamo website in the Investors and Media section under Events. Available materials will be found on the Sangamo website after the event under Presentations.

    Conference Call

    The Sangamo management team will hold a corporate call to further discuss program and financial updates on Monday, March 17, at 4:30pm Eastern Time.

    Participants should register for, and access, the call using this link. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly.

    An updated corporate presentation is available in the Investors and Media section under Presentations.

    The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under Events. A replay will be available following the conference call, accessible at the same link.

    About Sangamo Therapeutics

    Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to: Sangamo's cash runway and ability to continue to operate as a going concern; the therapeutic and commercial potential and value of Sangamo's product candidates, including the durability of therapeutic effects, the therapeutic and commercial potential and value of technologies used by Sangamo in its product candidates; the potential of its adeno-associated virus capsid delivery platform; the potential for isaralgagene civaparvovec to qualify for the FDA's Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval, expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civaparvovec, and the timing of such submission, and the potential to accelerate the expected timeline to approval; the anticipated advancement of isaralgagene civaparvovec to registration, including Sangamo's plans to seek a potential commercialization partner; Sangamo's ability to realize the expected benefits of the license agreements with Genentech and Astellas, including the potential for Sangamo to receive licensed target fees and milestone payments and royalties; Sangamo's ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including its ability to secure a commercialization partner for its Fabry disease program and additional collaborations with respect to Sangamo's hemophilia A program, STAC-BBB capsid delivery platform and epigenetic regulation capabilities; anticipated revenues from existing and new collaborations and the timing thereof; the anticipated plans and timelines of Sangamo and its collaborators in conducting our ongoing and potential future clinical trials and presenting clinical data from such clinical trials; the advancement of Sangamo's preclinical neurology programs, including the potential of ST-503 to transform the chronic neuropathic pain landscape, plans to initiate patient enrollment and dosing for ST-503 and announcement of such preliminary proof of efficacy data, and anticipated prion disease CTA submission and announcement of related preliminary clinical data; Sangamo's estimates regarding the sufficiency of its cash resources and its expenses, capital requirements and need for substantial additional financing; Sangamo's 2025 financial guidance related to GAAP and non-GAAP total operating expenses, impairments and non-cash stock-based compensation expense, depreciation and amortization; plans to participate in industry and investor conferences; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain funding or partnerships, in particular for its Fabry disease program, or additional collaboration partners necessary to advance its preclinical and clinical programs and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and/or seek protection under the U.S. Bankruptcy Code, the potential for collaborators and licensees to breach or terminate their agreements with Sangamo; the potential for Sangamo to fail to realize its expected benefits from its collaboration and license agreements; the uncertain and costly research and development process, including the risk that preclinical results may not be indicative of results in any future clinical trials; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any registrational trial of Sangamo's product candidates; the potential for technological developments that obviate technologies used by Sangamo; Sangamo's reliance on collaborators and its potential inability to secure additional collaborations, and Sangamo's ability to achieve expected future operating results.

    All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's financial guidance, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its collaborators will be able to develop commercially viable products or that Sangamo will earn any milestone or royalty payments under its collaboration agreements. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo's Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

    Non-GAAP Financial Measures

    To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP operating expenses, which excludes depreciation and amortization, stock-based compensation expense and impairment of goodwill, indefinite-lived intangible assets and long-lived assets from GAAP operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded depreciation and amortization, and stock-based compensation expense because they are non-cash expenses that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of goodwill, indefinite-lived intangible assets and long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.

    SELECTED CONSOLIDATED FINANCIAL DATA
    (Unaudited; in thousands, except per share amounts)
     
    Statement of Operations Data:
    Three months ended Year Ended
    December 31, December 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     
    Revenues

    $

    7,551

     

    $

    2,042

     

    $

    57,800

     

    $

    176,232

     

    Operating expenses:
    Research and development

     

    23,675

     

     

    50,706

     

     

    111,521

     

     

    234,057

     

    General and administrative

     

    9,866

     

     

    13,099

     

     

    44,727

     

     

    61,167

     

    Impairment of long-lived assets

     

    -

     

     

    296

     

     

    5,521

     

     

    65,528

     

    Impairment of goodwill and indefinite-lived intangible assets

     

    -

     

     

    -

     

     

    -

     

     

    89,485

     

    Total operating expenses

     

    33,541

     

     

    64,101

     

     

    161,769

     

     

    450,237

     

    Loss from operations

     

    (25,990

    )

     

    (62,059

    )

     

    (103,969

    )

     

    (274,005

    )

    Interest and other income, net

     

    2,167

     

     

    1,491

     

     

    5,861

     

     

    11,102

     

    Loss before income taxes

     

    (23,823

    )

     

    (60,568

    )

     

    (98,108

    )

     

    (262,903

    )

    Income tax benefit

     

    (427

    )

     

    (272

    )

     

    (167

    )

     

    (5,072

    )

    Net loss

    $

    (23,396

    )

    $

    (60,296

    )

    $

    (97,941

    )

    $

    (257,831

    )

    Basic and diluted net loss per share

    $

    (0.11

    )

    $

    (0.34

    )

    $

    (0.49

    )

    $

    (1.48

    )

    Shares used in computing basic and diluted net loss per share

     

    210,185

     

     

    177,619

     

     

    201,699

     

     

    174,444

     

     
     
    Selected Balance Sheet Data:
    December 31, 2024 December 31, 2023
     
    Cash, cash equivalents and marketable securities

    $

    41,918

     

    $

    81,002

     

    Total assets

    $

    101,635

     

    $

    165,320

     

    Total stockholders' equity

    $

    22,770

     

    $

    82,887

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250317620537/en/

    Investor Relations & Media Inquiries

    Louise Wilkie

    [email protected]

    [email protected]

    Get the next $SGMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

      5/16/23 8:00:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

      CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

      11/22/21 7:00:00 AM ET
      $ORGO
      $PACB
      $SGMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

      5/24/21 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/12/24 4:53:35 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/4/24 1:54:32 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      8/16/24 6:40:25 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SGMO
    Financials

    Live finance-specific insights

    See more
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

      All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive. Productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA provided clear CMC pathway to planned Biologics License Application (BLA) submission. Pivotal data readout expected by end of second quarter of 2025. Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagen

      5/6/25 8:30:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

      One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid

      4/28/25 4:31:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics upgraded by Truist with a new price target

      Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

      12/13/24 8:18:20 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

      12/10/24 11:58:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

      11/3/23 7:45:03 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati

      3/17/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this

      3/6/25 4:05:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GEN. COUNSEL & SECRETARY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 782,976 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:10:48 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 779,937 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:09:40 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,325,898 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:08:28 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    SEC Filings

    See more
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      5/6/25 4:03:49 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Sangamo Therapeutics Inc.

      10-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:05:16 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:01:39 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care